Docetaxel and S-1 for Advanced Gastric Cancer
Author Information
Author(s): Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, Komatsu Y, Kato T, Saitoh S, Akiya T, Munakata M, Miyata Y, Maeda Y, Takiuchi H, Nakano S, Esaki T, Kinjo F, Sakata Y
Primary Institution: Saitama Cancer Centre
Hypothesis
Docetaxel combined with S-1 would confer a clinically meaningful improvement in overall response rate and median survival, with a manageable safety profile.
Conclusion
The combination of docetaxel and S-1 is an active and well-tolerated regimen in patients with advanced gastric cancer.
Supporting Evidence
- The overall response rate was 46%.
- The median overall survival was estimated to be 14 months.
- 67% of patients experienced grade 3/4 neutropenia.
Takeaway
Doctors tested a new medicine combination to help people with stomach cancer, and it worked pretty well without too many bad side effects.
Methodology
This was a multicentre, open-label, single-arm, phase I/II study conducted at 16 institutions in Japan.
Limitations
The median survival observed may be influenced by poststudy chemotherapy, which was administered to 78% of patients.
Participant Demographics
{"median_age":65,"age_range":"42-79","sex_distribution":{"male":31,"female":15},"prior_chemotherapy":{"received":16,"not_received":30}}
Statistical Information
Confidence Interval
{"overall_response_rate":"95% CI, 31–61%","median_overall_survival":"95% CI, 8.3–17.3"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website